载依非韦伦固体脂质纳米粒提高口服生物利用度的设计与评价

International Journal of Pharmaceutical Sciences and Nanotechnology Pub Date : 2021-12-01 DOI:10.37285/ijpsn.2021.14.6.8

Harshita Gupta, Ashish K. Srivastava

{"title":"载依非韦伦固体脂质纳米粒提高口服生物利用度的设计与评价","authors":"Harshita Gupta, Ashish K. Srivastava","doi":"10.37285/ijpsn.2021.14.6.8","DOIUrl":null,"url":null,"abstract":"Present work illustrates that efavirenz-loaded solid lipid nanoparticles were prepared with the objective of increasing bioavailability and protection of drugs due to biocompatible lipidic content. Efavirenz is generally used for the treatment of HIV. Selection of the suitable lipid phase, surfactant, and cosurfactant was done by individual screening method with the construction of pseudo-ternary phase study. The formulations were prepared by the microemulsion method followed by the lyophilization technique. EFV-SLN has shown a mean particle size of 55.73 ± 3.9 nm having a PDI of 0.153 ± 0.451. Zeta potential was found to be -9.98mV and the formulation was found stable. In vivo pharmaco-kinetic studies exhibited 5.41-fold enhancement in peak plasma concentration (","PeriodicalId":14382,"journal":{"name":"International Journal of Pharmaceutical Sciences and Nanotechnology","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Design and Evaluation of Efavirenz Loaded Solid Lipid Nanoparticle for Boosting Oral Bioavailability\",\"authors\":\"Harshita Gupta, Ashish K. Srivastava\",\"doi\":\"10.37285/ijpsn.2021.14.6.8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Present work illustrates that efavirenz-loaded solid lipid nanoparticles were prepared with the objective of increasing bioavailability and protection of drugs due to biocompatible lipidic content. Efavirenz is generally used for the treatment of HIV. Selection of the suitable lipid phase, surfactant, and cosurfactant was done by individual screening method with the construction of pseudo-ternary phase study. The formulations were prepared by the microemulsion method followed by the lyophilization technique. EFV-SLN has shown a mean particle size of 55.73 ± 3.9 nm having a PDI of 0.153 ± 0.451. Zeta potential was found to be -9.98mV and the formulation was found stable. In vivo pharmaco-kinetic studies exhibited 5.41-fold enhancement in peak plasma concentration (\",\"PeriodicalId\":14382,\"journal\":{\"name\":\"International Journal of Pharmaceutical Sciences and Nanotechnology\",\"volume\":\"62 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmaceutical Sciences and Nanotechnology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37285/ijpsn.2021.14.6.8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical Sciences and Nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37285/ijpsn.2021.14.6.8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目前的研究表明，负载依非韦伦的固体脂质纳米颗粒的制备是为了提高生物利用度和保护药物，因为生物相容性脂质含量。依非韦伦通常用于治疗艾滋病毒。通过个体筛选法选择合适的脂相、表面活性剂和助表面活性剂，并进行拟三元相构建研究。采用微乳法和冻干法制备了该制剂。EFV-SLN的平均粒径为55.73±3.9 nm, PDI为0.153±0.451。Zeta电位为-9.98mV，配方稳定。体内药物动力学研究显示血药浓度峰值提高5.41倍(

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Design and Evaluation of Efavirenz Loaded Solid Lipid Nanoparticle for Boosting Oral Bioavailability

Present work illustrates that efavirenz-loaded solid lipid nanoparticles were prepared with the objective of increasing bioavailability and protection of drugs due to biocompatible lipidic content. Efavirenz is generally used for the treatment of HIV. Selection of the suitable lipid phase, surfactant, and cosurfactant was done by individual screening method with the construction of pseudo-ternary phase study. The formulations were prepared by the microemulsion method followed by the lyophilization technique. EFV-SLN has shown a mean particle size of 55.73 ± 3.9 nm having a PDI of 0.153 ± 0.451. Zeta potential was found to be -9.98mV and the formulation was found stable. In vivo pharmaco-kinetic studies exhibited 5.41-fold enhancement in peak plasma concentration (

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Pharmaceutical Sciences and Nanotechnology

CiteScore

0.50

自引率

0.00%

发文量